PDS Biotech appoints Stephan Toutain as COO; grants 200,000-share option

PDS Biotechnology Corp

Stephan Toutain named COO effective May 1, 2024; brings 30+ years pharma experience including oncology and orphan drugs.
Annual salary $450,000; eligible for annual performance bonus of 40% of base salary.
Received inducement stock option for 200,000 shares at $3.61 per share, vesting over four years under Nasdaq Listing Rule 5635(c)(4).
Prior roles include COO at Anavex Life Sciences (2018-2024) and leadership at Alnylam, Sarepta, Alexion, Celgene, and Johnson & Johnson.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Stephan F. Toutain

Chief Operations Officer

PDSB · PDS Biotechnology Corp

Effective: 2024-05-01
Filed: May 2, 2024, 7:59 PM ET

PDS Biotechnology Corporation (the “Company”) entered into an Executive Employment Agreement with Stephan F. Toutain (the “Employment Agreement”), pursuant to which Mr. Toutain will assume the role of the Company’s Chief Operations Officer, effective as of May 1, 2024 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Stephan F. Toutain was appointed as Chief Operations Officer at PDS Biotechnology Corp.

Action: appointed
Role: Chief Operations Officer

Exact text from the filing

PDS Biotechnology Corporation (the “Company”) entered into an Executive Employment Agreement with Stephan F. Toutain (the “Employment Agreement”), pursuant to which Mr. Toutain will assume the role of the Company’s Chief Operations Officer, effective as of May 1, 2024 (the “Effective Date”).

View on SEC.gov

PDS Biotechnology Corp filing history →

Source: SEC EDGAR

accession 0001140361-24-023815

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.